Drug Trial News -
An NOP survey, released today by Cancer Research UK's Race for Life, reveals that only three per cent of those surveyed know that people who are overweight are more likely to develop cancer than people of normal weight, while 70 per cent are aware of the link with heart disease.
Pharmaceutical News -
Schering AG Group, Germany has announced that the Swedish health authority MPA has granted marketing approval for its innovative liver imaging product Primovist(TM) (gadoxetic acid disodium). Primovist(TM) is designed for the detection and characterization of liver lesions by magnetic resonance imaging (MRI) including liver tumors, metastases as well as other malignant and benign lesions.
Child Health News -
Researchers at the Johns Hopkins Children's Center have designed an online, Web-based system for ordering total parenteral nutrition (TPN) that identifies and pre-emptively eliminates potentially serious calculation errors.
Drug Trial News -
A major cause of patient pain and suffering and additional healthcare costs in hospitals and aged care facilities - pressure ulcers (bed sores)- can be more than halved by using a simple but effective bedding overlay product developed by CSIRO.
Medical Procedure News -
A new theory of joint function presented in a symposium at the 71st annual meeting of the American Academy of Orthopaedic Surgeons suggests that the development of osteoarthritis in the knee following an injury may be both predictable and preventable.
Pharmaceutical News -
In order to ensure the availability of influenza vaccine for administration early this coming fall, the AMA recommends that physicians and providers begin to order supplies of influenza vaccine immediately. In 2003, large numbers of cases of influenza began to appear in October, and activity was widespread.
Medical Science News -
The AMA is co-sponsoring a symposium for CME credit this month in Tampa, Fla., on the medical and public health aspects of mercury exposure. "Mercury: Medical and Public Health Issues" will be held from April 28-30 at the Tampa Marriott Waterside Hotel and Marina.
Pharmaceutical News -
Merck/Schering-Plough Pharmaceuticals today announced the regulatory approval of INEGYTM (ezetimibe/simvastatin) in Germany for the treatment of elevated cholesterol (hypercholesterolemia). INEGY is the first product to reduce low-density lipoprotein cholesterol (LDL-C or ‘bad’ cholesterol), along with diet and exercise, through dual inhibition by inhibiting cholesterol production in the liver and absorption in the intestine. The approval of INEGY in Germany represents the first approval in Europe for ezetimibe/simvastatin tablets and the first step in seeking marketing approval throughout the European Union (EU) under the EU’s mutual recognition procedure.